^
    Back
    Association details:
    Biomarker:EGFR mutation
    Cancer:Lung Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor) +
    Tagrisso (osimertinib) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers

    Excerpt:
    ...Somatic activating mutation in EGFR...
    Trial ID:
    NCT02803203
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    JAMA Oncol
    Title:

    Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers A Phase 1/2 Single-Group Open-Label Trial

    Published date:
    05/28/2020
    Excerpt:
    The combination of osimertinib and bevacizumab met the study’s prespecified effectiveness end point. Persistent EGFR-mutant circulating tumor DNA at 6 weeks was associated with early progression and shorter survival.
    DOI:
    10.1001/jamaoncol.2020.1260
    Trial ID:
    NCT02803203